SCHEMBL3589018

SCHEMBL3589018

O=C(Nc1cnccc1Cl)c1ccc(OCCCCl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
STAT3 P40763 1/20 0.53
CHRNB2 P17787 1/20 0.50
CHRNB4 P30926 1/20 0.50
CHRNA3 P32297 1/20 0.50
CHRNA4 P43681 1/20 0.50
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
GSK3A P49840 1/20 0.48
GSK3B P49841 1/20 0.48
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 3/20 0.46
NFKB1 P19838 1/20 0.46
CASP3 P42574 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3671003 0.82 RAB9A (0.60) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL30785562 0.80 KMT2A (0.61) LMNASMN1; SMN2NPC1RAB9AGSK3A
SCHEMBL23458450 0.79 GSK3A (0.60) LMNARAB9AGSK3AGSK3BKDM4E
SCHEMBL17984931 0.77 CYP11B1 (0.56) LMNASMN1; SMN2NPC1RAB9AGSK3A
SCHEMBL321601 0.77 CYP11B1 (0.56) LMNANPC1RAB9AGSK3AGSK3B
SCHEMBL13542099 0.76 KMT2A (0.41) LMNASMN1; SMN2STAT3NPC1KDM4E
SCHEMBL29678458 0.73 ALDH1A1 (0.48) LMNASMN1; SMN2GSK3AGSK3BALDH1A1
SCHEMBL7806605 0.71 NPC1 (0.58) LMNASMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL25406163 0.71 BCHE (0.67) SMN1; SMN2NPC1RAB9ACASP3SENP7
SCHEMBL25680395 0.70 MAPT (0.51) LMNASMN1; SMN2NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands UCB PHARMA, S.A. (BE) 2010-01-14 US disclosed
EP-2049548-A1 FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS UCB Pharma, S.A. (BE) 2009-04-22 EP disclosed
WO-2008012010-A1 FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS UCB PHARMA, S.A. (BE) 2008-01-31 WO disclosed
WO-2008012010-A1 FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS UCB PHARMA, S.A. (BE) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands HRH3, HRH4, HRH2 LMNA 4665/4885SMN1; SMN2 4815/4885STAT3 2453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.